This formulation is a balanced blend of long-acting metabolic peptides (the well-known CagriSema research system), composed of semaglutide and canagliflozin, two active components. The two pathways of action are completely non-overlapping and highly complementary, unlike single GLP-1 target raw materials. It simultaneously covers intestinal hormone regulation and the amylin metabolic pathway, making it the most synergistic composite model system currently used in research on obesity, glucose metabolism, and appetite mechanisms. Many research groups prioritize using this formulation as a control for advanced metabolic experiments and comparing the efficacy of single peptides.
**Core Functions and Physical Mechanisms**
This combination is the highly anticipated "CagriSema," a long-acting, injectable dual-receptor agonist combination formulation. At the physical and molecular level, it achieves a synergistic complementarity of two potent mechanisms:
1. **Semaglutide:** As a GLP-1 receptor agonist, it mimics the intestinal hormone GLP-1, activating the hypothalamic appetite regulation center to suppress appetite and delay gastric emptying, thereby significantly reducing calorie intake.
2. **Cagrilintide:** As a long-acting amyloid analog, it targets and binds to amyloid receptors in the brainstem and periphery. Its unique mechanism lies in further suppressing appetite through non-GLP-1 pathways and regulating glucagon secretion.
The combination of these two simultaneously activates two independent metabolic pathways, GLP-1 and amylin, producing a synergistic effect of "1+1>2." While significantly reducing weight, Cagrilintide's unique mechanism effectively alleviates gastrointestinal adverse reactions such as nausea and vomiting that may be caused by using GLP-1 agonists alone.
**Applicable Scenarios**
Currently, this product is primarily in Phase III clinical trials for obesity and type 2 diabetes. This combination is highly anticipated, aiming to provide a more effective weight loss and glycemic control solution for severely obese patients and those with metabolic disorders who have encountered plateaus in the effectiveness of single GLP-1 drugs (such as semagraft alone) or cannot tolerate the side effects of high doses.
Storage Conditions
Lyophilized powder: -20℃, sealed, protected from light, and with desiccant. Maximum storage time is 24–36 months. Short-term working storage at 2–8℃ is also acceptable (do not exceed 24 months). Do not store on the refrigerator door shelf, and do not store with fruits and vegetables; shaking will cause the powder to absorb moisture and clump.
Reconstitute only with BAC water (containing 0.9% benzyl alcohol antibacterial solution). Do not use physiological saline (acyl peptides are prone to precipitation and clouding). Slowly push along the bottle wall and gently roll for 2–5 minutes. Do not shake or jiggle-Cagri contains Cys2–Cys7 disulfide bonds; vigorous shearing will cause it to clump and become inactive.
After preparing the theoretical concentration, check the volume of water added: adding 2 mL yields a total concentration of 5 mg/mL (Cagri 2.5 + Sema 2.5), and adding 3 mL yields a total concentration of 3.33 mg/mL. The liquid should be used within 28–30 days, protected from light at 2–8℃; discard any expired liquid.
Never freeze the liquid. A single freeze-thaw cycle will damage disulfide bonds and acylated side chains, rendering the entire bottle unusable. After removing it from the freezer, allow it to reach room temperature for 15 minutes before opening to prevent condensation from entering.
Precautions:
First and foremost: This is not a weight-loss drug; it is a prescription drug and has not yet been officially approved in major global markets (the FDA is expected to make a decision by the end of 2026, and the EMA and MHRA are still reviewing it). If you see someone selling "research-grade" raw materials or so-called "combination formulations" online, my advice is-don't touch them. Preparing your own dosage and administering injections yourself is not bravery; it's gambling with your life.
Gastrointestinal reactions are unavoidable. Nausea, vomiting, diarrhea, and constipation are common in clinical trials. Because both Cagrilintide and Semaglutide delay gastric emptying, the combined effect may exacerbate gastroparesis. Therefore, the dosage must be increased slowly, starting with a low dose to allow the body to gradually adapt. Initiating a high dose immediately is simply self-inflicted suffering.
Regarding contraindications, individuals with a personal or family history of medullary thyroid carcinoma (MTC) are absolutely contraindicated-this is a black box warning for the entire GLP-1 receptor agonist class, with no room for negotiation. A history of pancreatitis, severe gastrointestinal diseases (such as existing gastroparesis), and gallbladder disease also require extra caution. Pregnant women, breastfeeding mothers, and adolescents under 18 years of age are currently advised against using this medication.
Another point many people easily overlook is that even the strongest drug is only an adjunct therapy and must be combined with a low-calorie diet and exercise. Expecting to take an injection once a week and then eat and drink whatever you want? Weight rebound is only a matter of time. Furthermore, appetite will return after stopping the medication, and gastric emptying will resume. If lifestyle habits aren't changed, the weight lost will eventually be regained.
Finally, let's reiterate the 5mg + 5mg issue: there are currently no clinical trials validating this dosage. 2.4/2.4mg is already sufficient for most people to lose over 20% of their weight. Increasing the dosage prematurely not only presents uncertain benefits but could also exponentially increase side effects. If you really want to use this combination, wait until it's officially available and consult an endocrinologist, using the approved dosage under monitoring-this is the responsible approach.
Hot Tags: Bestselling combination peptides: Cagrilintide 5mg + Semaglutide 5mg, China Bestselling combination peptides: Cagrilintide 5mg + Semaglutide 5mg manufacturers, suppliers, factory
